Evaluation of megadose vitamin therapy in an experimental brain tumor

Newell, Samuel D.; Kapp, John P.; Romfh, John H.

doi:10.1016/0090-3019(81)90125-7

Cited by 8 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The survival rate of the tumor-bearing animals was increased after the treatment with vitamins B12 and C, and no apparent toxic side effect on the host was observed [14,16]. However, results of an experiment with Fisher CDF rats indicated that a mixture of vitamins B12 and C had no effect on the growth of L9 gliosarcoma in rats and that no difference in survival time between treatment group and control group was observed [ 17].…”

mentioning

confidence: 89%

Cytotoxic Activity of Cobalamin in Cultured Malignant and Nonmalignant Cells

1990

View full text Add to dashboard Cite

The cytotoxic effect of cobalamin (vitamin B₁₂) on the growth of malignant and nonmalignant cell lines in culture has been examined. Among the four cobalamins studied, 5’-deoxyadenosylcobalamin, an enzymatically active derivative, was an effective cytotoxic agent. The data indicated that adenosylcobalamin seemed to act selectively on fast-growing malignant cells. Methylcobalamin was also effective at elevated concentrations. Cyanocobalamin was not toxic to all cell lines studied. Hydroxocobalamin at very high concentrations was able to slightly decrease growth of certain cell lines. The results support the hypothesis that the cytotoxic effect of cobalamin was associated with the metabolic activities of this vitamin at the cellular level. Also, cobalamin may be a potential antitumor agent.

show abstract

mentioning

confidence: 89%

Cytotoxic Activity of Cobalamin in Cultured Malignant and Nonmalignant Cells

1990

View full text Add to dashboard Cite

show abstract

“…In 1981, Newell et al used a mixture of vitamins C and B12 in high dose on rats with glioma. They observed no difference in survival time between experimental and control groups [49].…”

Section: Animal Studiesmentioning

confidence: 91%

Antioxidant Supplementation during Glioma Therapy: Friend or Foe?

Harmancı¹

2019

Glioma - Contemporary Diagnostic and Therapeutic Approaches

View full text Add to dashboard Cite

Gliomas which are one of the most common types of primary brain tumors are originated from glial cells. Type of tumor and tumor location are the most important factors to determine the treatment options. The treatment options might be surgery, radiation therapy, chemotherapy, targeted therapies, and experimental clinical studies. Especially, in course of chemotherapy and radiotherapy, antioxidant levels decrease. Antioxidants fight against the oxidants' negative effects, which include cell damage, oxidative stress, and so on. Recent years, some researchers present that the antioxidant using could be harmful in some cases. A growing body of evidence suggests that antioxidant supplementation might increase the mortality. In this chapter, an overview of antioxidants and their functions has been presented to introduce researchers to the changes and effects of the antioxidants in glioma treatment. The evidence-based studies have been summarized. These experimental studies are important to understand the right option for the patient and transfer the solution from bench to bed.

show abstract

“…Studies have demonstrated that vitamin C was selectively concentrated in tumors and may form cytotoxic quantities of hydrogen peroxide (H 2 O 2 ) within the tumor as a byproduct of oxidation [ 13 , 15 , 16 ]. Vitamin C can act as a prodrug to deliver a substantial influx of H 2 O 2 to tumors after intravenous (IV) administration [ 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

“…Vitamin C intake as a dietary antioxidant was capable of augmenting growth restriction of cancer cells in general and glioma cells to be specific [11,12]. Studies have shown that vitamin C was capable of inhibiting cancer via mechanism, such as the argumentation of stromal integrity of normal tissue, activating lymphocytes to a greater level of immunocompetence, stimulating "auspicious modification in the steroid environment," blocking hyaluronidase activity in malignant cells, augmenting antiviral activity, and interfering with the metabolism of malignant cells [13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Exploring the Pivotal Neurophysiologic and Therapeutic Potentials of Vitamin C in Glioma

Richard¹,

Sackey

Kortei

2021

Journal of Oncology

View full text Add to dashboard Cite

Gliomas represent solely primary brain cancers of glial cell or neuroepithelial origin. Gliomas are still the most lethal human cancers despite modern innovations in both diagnostic techniques as well as therapeutic regimes. Gliomas have the lowest overall survival rate compared to other cancers 5 years after definitive diagnosis. The dietary intake of vitamin C has protective effect on glioma risk. Vitamin C is an essential compound that plays a vital role in the regulation of lysyl and prolyl hydroxylase activity. Neurons store high levels of vitamin C via sodium dependent-vitamin C transporters (SVCTs) to protect them from oxidative ischemia-reperfusion injury. Vitamin C is a water-soluble enzyme, typically seen as a powerful antioxidant in plants as well as animals. The key function of vitamin C is the inhibition of redox imbalance from reactive oxygen species produced via the stimulation of glutamate receptors. Gliomas absorb vitamin C primarily via its oxidized dehydroascorbate form by means of GLUT 1, 3, and 4 and its reduced form, ascorbate, by SVCT2. Vitamin C is able to preserve prosthetic metal ions like Fe2+ and Cu+ in their reduced forms in several enzymatic reactions as well as scavenge free radicals in order to safeguard tissues from oxidative damage. Therapeutic concentrations of vitamin C are able to trigger H2O2 generation in glioma. High-dose combination of vitamin C and radiation has a much more profound cytotoxic effect on primary glioblastoma multiforme cells compared to normal astrocytes. Control trials are needed to validate the use of vitamin C and standardization of the doses of vitamin C in the treatment of patients with glioma.

show abstract

Evaluation of megadose vitamin therapy in an experimental brain tumor

Cited by 8 publications

References 9 publications

Cytotoxic Activity of Cobalamin in Cultured Malignant and Nonmalignant Cells

Cytotoxic Activity of Cobalamin in Cultured Malignant and Nonmalignant Cells

Antioxidant Supplementation during Glioma Therapy: Friend or Foe?

Exploring the Pivotal Neurophysiologic and Therapeutic Potentials of Vitamin C in Glioma

Contact Info

Product

Resources

About